NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced a key leadership transition as founder and ...

The pharmaceutical sector has been making headlines for large-scale layoffs, department closures and clinical trial failures.

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a ...

Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United ...

Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it ...

(Reuters) -Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for the unusually large number of drugs affected. Among the companies facing ...

A recent federal court decision highlights the delicate balance between U.S. Food and Drug Administration (FDA) guidance and trade dress ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic diseases, as outlined at the Academy of Managed Care Pharmacy annual ...

After Novartis’ patent on the blockbuster blood pressure medication Entresto was found invalid at the district court for covering technology that was developed after the patent was filed ...

Ltd.'s Entresto copy, preserving MSN’s chance to launch earlier if it convinces the judge to order a key patent be pulled from a registry of approved drugs. Sending the judgment to the US Food and ...